BR112015006623A2 - laquinimod e pridopidina para o tratamento de doenças neurodegenerativas - Google Patents
laquinimod e pridopidina para o tratamento de doenças neurodegenerativasInfo
- Publication number
- BR112015006623A2 BR112015006623A2 BR112015006623A BR112015006623A BR112015006623A2 BR 112015006623 A2 BR112015006623 A2 BR 112015006623A2 BR 112015006623 A BR112015006623 A BR 112015006623A BR 112015006623 A BR112015006623 A BR 112015006623A BR 112015006623 A2 BR112015006623 A2 BR 112015006623A2
- Authority
- BR
- Brazil
- Prior art keywords
- pridopidine
- laquinimod
- treatment
- dhq
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
resumo laquinimod e pridopidina para o tratamento de doenças neurodegenerativas esta invenção fornece um método de tratamento de um paciente acometido com uma doença neurodegenerativa, por exemplo, doença de huntington (dhq), que compreende a administração de laquinimod ao paciente como uma terapia adjuvante ou em combinação com pridopidina. esta invenção também proporciona uma embalagem e uma composição farmacêutica compreendendo laquinimod e pridopidina para o tratamento de um paciente acometido com uma doença neurodegenerativa, por exemplo, dhq. esta invenção também fornece laquinimod para utilização como uma terapia adjuvante ou em combinação com pridopidina no tratamento de um paciente acometido com uma doença neurodegenerativa, por exemplo, dhq. esta invenção fornece ainda a utilização de laquinimod e pridopidina na preparação de uma combinação para o tratamento de um paciente acometido com uma doença neurodegenerativa, por exemplo, dhq.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706695P | 2012-09-27 | 2012-09-27 | |
US201361879004P | 2013-09-17 | 2013-09-17 | |
PCT/US2013/062482 WO2014052933A1 (en) | 2012-09-27 | 2013-09-27 | Laquinimod and pridopidine for treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015006623A2 true BR112015006623A2 (pt) | 2017-07-04 |
Family
ID=50339469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015006623A BR112015006623A2 (pt) | 2012-09-27 | 2013-09-27 | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas |
Country Status (13)
Country | Link |
---|---|
US (7) | US20150209346A1 (pt) |
EP (1) | EP2900330A4 (pt) |
CN (1) | CN104902958A (pt) |
AU (1) | AU2013323131A1 (pt) |
BR (1) | BR112015006623A2 (pt) |
CA (1) | CA2884781A1 (pt) |
EA (1) | EA201590655A8 (pt) |
HK (2) | HK1211525A1 (pt) |
IL (1) | IL237742A0 (pt) |
IN (1) | IN2015DN03219A (pt) |
MX (1) | MX2015003608A (pt) |
WO (1) | WO2014052933A1 (pt) |
ZA (1) | ZA201502600B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
AU2008239841B2 (en) * | 2007-04-12 | 2013-07-18 | Teva Pharmaceuticals International Gmbh | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
US20130197031A1 (en) | 2010-09-03 | 2013-08-01 | IVAX International GmbH | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
JP6189299B2 (ja) | 2011-09-07 | 2017-08-30 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジン塩酸塩の新規な多形形態 |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
MX2015017307A (es) | 2013-06-21 | 2016-08-03 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. |
CA2933380A1 (en) * | 2013-12-20 | 2015-06-25 | Esther Lukasiewicz Hagai | Use of laquinimod to delay huntington's disease progression |
TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016044103A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
CA2970799A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
JP6887952B2 (ja) * | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
JP7082186B2 (ja) | 2017-08-14 | 2022-06-07 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンによる筋萎縮性側索硬化症の治療方法 |
BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2528040T3 (es) * | 2007-06-18 | 2015-02-03 | A.Carlsson Research Ab | Uso de estabilizadores de dopamina |
BRPI0920927A2 (pt) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | derivados de azaquinolinona e usos dos mesmos |
SI2467372T1 (sl) * | 2009-08-10 | 2016-09-30 | Teva Pharmaceutical Industries Ltd. | Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
EA201390827A1 (ru) * | 2010-12-07 | 2013-12-30 | Тева Фармасьютикал Индастриз Лтд. | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом |
-
2013
- 2013-09-27 US US14/426,327 patent/US20150209346A1/en not_active Abandoned
- 2013-09-27 EP EP13840841.4A patent/EP2900330A4/en not_active Withdrawn
- 2013-09-27 WO PCT/US2013/062482 patent/WO2014052933A1/en active Application Filing
- 2013-09-27 CA CA2884781A patent/CA2884781A1/en active Pending
- 2013-09-27 AU AU2013323131A patent/AU2013323131A1/en not_active Abandoned
- 2013-09-27 US US14/040,586 patent/US20140088140A1/en not_active Abandoned
- 2013-09-27 MX MX2015003608A patent/MX2015003608A/es unknown
- 2013-09-27 BR BR112015006623A patent/BR112015006623A2/pt active Search and Examination
- 2013-09-27 EA EA201590655A patent/EA201590655A8/ru unknown
- 2013-09-27 IN IN3219DEN2015 patent/IN2015DN03219A/en unknown
- 2013-09-27 CN CN201380050913.8A patent/CN104902958A/zh active Pending
-
2015
- 2015-03-15 IL IL237742A patent/IL237742A0/en unknown
- 2015-04-17 ZA ZA2015/02600A patent/ZA201502600B/en unknown
- 2015-12-15 HK HK15112317.4A patent/HK1211525A1/xx unknown
-
2016
- 2016-03-01 HK HK16102362.8A patent/HK1214553A1/zh unknown
-
2017
- 2017-07-20 US US15/655,580 patent/US20170319569A1/en not_active Abandoned
- 2017-11-02 US US15/801,703 patent/US20180133209A1/en not_active Abandoned
-
2018
- 2018-05-08 US US15/974,112 patent/US20180250285A1/en not_active Abandoned
- 2018-08-30 US US16/117,604 patent/US20180369228A1/en not_active Abandoned
- 2018-12-18 US US16/223,993 patent/US20190117639A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA201590655A8 (ru) | 2016-07-29 |
US20180250285A1 (en) | 2018-09-06 |
US20180133209A1 (en) | 2018-05-17 |
US20170319569A1 (en) | 2017-11-09 |
AU2013323131A1 (en) | 2015-05-07 |
HK1211525A1 (en) | 2016-05-27 |
US20180369228A1 (en) | 2018-12-27 |
US20150209346A1 (en) | 2015-07-30 |
US20190117639A1 (en) | 2019-04-25 |
MX2015003608A (es) | 2015-06-05 |
EP2900330A1 (en) | 2015-08-05 |
IN2015DN03219A (pt) | 2015-10-02 |
IL237742A0 (en) | 2015-05-31 |
US20140088140A1 (en) | 2014-03-27 |
CN104902958A (zh) | 2015-09-09 |
ZA201502600B (en) | 2016-06-29 |
HK1214553A1 (zh) | 2016-07-29 |
WO2014052933A1 (en) | 2014-04-03 |
EP2900330A4 (en) | 2016-05-25 |
EA201590655A1 (ru) | 2015-12-30 |
CA2884781A1 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112015020804A2 (pt) | dispositivo fototerapeutico, método e uso | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
BR112017028132A2 (pt) | métodos de tratamento de malignidade hematológica usando terapia combinada de inibidor de mtor em nanopartícula | |
BR112015007778A2 (pt) | profármacos neutralizantes de vegf para o tratamento de condições oculares | |
BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
BR112014014181A2 (pt) | combinação de ozogamicina inotuzumab e torisel para o tratamento de câncer | |
BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
BR112017020039A2 (pt) | composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017004153A2 (pt) | métodos para tratamento de infecções por protozoários | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
BR112015015108A2 (pt) | cateter com marcações para facilitar o alinhamento | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2533 DE 23-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |